241 related articles for article (PubMed ID: 37401302)
21. Clinical Presentation and Outcome of Patients With Optic Pathway Glioma.
Robert-Boire V; Rosca L; Samson Y; Ospina LH; Perreault S
Pediatr Neurol; 2017 Oct; 75():55-60. PubMed ID: 28847625
[TBL] [Abstract][Full Text] [Related]
22. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations.
Sharif S; Upadhyaya M; Ferner R; Majounie E; Shenton A; Baser M; Thakker N; Evans DG
J Med Genet; 2011 Apr; 48(4):256-60. PubMed ID: 21278392
[TBL] [Abstract][Full Text] [Related]
23. Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children.
Ullrich NJ; Prabhu SP; Packer RJ; Goldman S; Robison NJ; Allen JC; Viskochil DH; Gutmann DH; Perentesis JP; Korf BR; Fisher MJ; Kieran MW;
Pediatr Blood Cancer; 2021 Apr; 68(4):e28833. PubMed ID: 33336845
[TBL] [Abstract][Full Text] [Related]
24. Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitors.
Jecrois ES; Zheng W; Bornhorst M; Li Y; Treisman DM; Muguyo D; Huynh S; Andrew SF; Wang Y; Jiang J; Pierce BR; Mao H; Krause MK; Friend A; Nadal-Nicolas F; Stasheff SF; Li W; Zong H; Packer RJ; Zhu Y
Dev Cell; 2021 Oct; 56(20):2871-2885.e6. PubMed ID: 34428430
[TBL] [Abstract][Full Text] [Related]
25. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
Friedrich RE; Nuding MA
Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
[TBL] [Abstract][Full Text] [Related]
26. Optic pathway glioma and the sex association in neurofibromatosis type 1: a single-center study.
Henning AM; Handrup MM; Kjeldsen SM; Larsen DA; Ejerskov C
Orphanet J Rare Dis; 2021 Nov; 16(1):489. PubMed ID: 34809690
[TBL] [Abstract][Full Text] [Related]
27. Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma.
Kim KY; Ju WK; Hegedus B; Gutmann DH; Ellisman MH
Neuroscience; 2010 Sep; 170(1):178-88. PubMed ID: 20600672
[TBL] [Abstract][Full Text] [Related]
28. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.
Listernick R; Ferner RE; Liu GT; Gutmann DH
Ann Neurol; 2007 Mar; 61(3):189-98. PubMed ID: 17387725
[TBL] [Abstract][Full Text] [Related]
29. RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth.
Solga AC; Pong WW; Kim KY; Cimino PJ; Toonen JA; Walker J; Wylie T; Magrini V; Griffith M; Griffith OL; Ly A; Ellisman MH; Mardis ER; Gutmann DH
Neoplasia; 2015 Oct; 17(10):776-88. PubMed ID: 26585233
[TBL] [Abstract][Full Text] [Related]
30. The impact of coexisting genetic mutations on murine optic glioma biology.
Kaul A; Toonen JA; Gianino SM; Gutmann DH
Neuro Oncol; 2015 May; 17(5):670-7. PubMed ID: 25246427
[TBL] [Abstract][Full Text] [Related]
31. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.
Fisher MJ; Loguidice M; Gutmann DH; Listernick R; Ferner RE; Ullrich NJ; Packer RJ; Tabori U; Hoffman RO; Ardern-Holmes SL; Hummel TR; Hargrave DR; Bouffet E; Charrow J; Bilaniuk LT; Balcer LJ; Liu GT
Neuro Oncol; 2012 Jun; 14(6):790-7. PubMed ID: 22474213
[TBL] [Abstract][Full Text] [Related]
32. The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.
Prada CE; Hufnagel RB; Hummel TR; Lovell AM; Hopkin RJ; Saal HM; Schorry EK
J Pediatr; 2015 Oct; 167(4):851-856.e1. PubMed ID: 26233602
[TBL] [Abstract][Full Text] [Related]
33. Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.
Diggs-Andrews KA; Brown JA; Gianino SM; Rubin JB; Wozniak DF; Gutmann DH
Ann Neurol; 2014 Feb; 75(2):309-16. PubMed ID: 24375753
[TBL] [Abstract][Full Text] [Related]
34. Estrogen-induced glial IL-1β mediates extrinsic retinal ganglion cell vulnerability in murine Nf1 optic glioma.
Tang Y; Chatterjee J; Wagoner N; Bozeman S; Gutmann DH
Ann Clin Transl Neurol; 2024 Mar; 11(3):812-818. PubMed ID: 38229454
[TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma.
Dasgupta B; Yi Y; Hegedus B; Weber JD; Gutmann DH
Cancer Res; 2005 Nov; 65(21):9843-50. PubMed ID: 16267007
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study.
Ullrich NJ; Prabhu SP; Reddy AT; Fisher MJ; Packer R; Goldman S; Robison NJ; Gutmann DH; Viskochil DH; Allen JC; Korf B; Cantor A; Cutter G; Thomas C; Perentesis JP; Mizuno T; Vinks AA; Manley PE; Chi SN; Kieran MW
Neuro Oncol; 2020 Oct; 22(10):1527-1535. PubMed ID: 32236425
[TBL] [Abstract][Full Text] [Related]
37. NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.
Toonen JA; Anastasaki C; Smithson LJ; Gianino SM; Li K; Kesterson RA; Gutmann DH
Hum Mol Genet; 2016 May; 25(9):1703-13. PubMed ID: 26908603
[TBL] [Abstract][Full Text] [Related]
38. Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1.
Sellmer L; Farschtschi S; Marangoni M; Heran MKS; Birch P; Wenzel R; Mautner VF; Friedman JM
Orphanet J Rare Dis; 2018 Apr; 13(1):62. PubMed ID: 29685181
[TBL] [Abstract][Full Text] [Related]
39. Brain gliomas, hydrocephalus and idiopathic aqueduct stenosis in children with neurofibromatosis type 1.
Glombova M; Petrak B; Lisy J; Zamecnik J; Sumerauer D; Liby P
Brain Dev; 2019 Sep; 41(8):678-690. PubMed ID: 31000370
[TBL] [Abstract][Full Text] [Related]
40. Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice.
Brown JA; Emnett RJ; White CR; Yuede CM; Conyers SB; O'Malley KL; Wozniak DF; Gutmann DH
Hum Mol Genet; 2010 Nov; 19(22):4515-28. PubMed ID: 20826448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
